# Third Coast Bancshares, Inc.: financial statements, quarterly

TCBX · NYSE · CIK 1781730 · [Financials](/sectors/financials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/tcbx.md) · [Financials](/companies/tcbx/financials.md) · [Filings](/companies/tcbx/filings.md) · [Insiders](/companies/tcbx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/tcbx/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Interest expense | $m | [34.1](/filings/0000950170-24-027956.md) | [39.7](/filings/0000950170-24-027956.md) | [40.8](/filings/0000950170-24-054517.md) | [42.4](/filings/0000950170-24-094013.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [1.4](/filings/0000950170-24-121492.md) | [2.3](/filings/0000950170-24-027956.md) | [2.6](/filings/0000950170-25-064535.md) | [3.4](/filings/0000950170-25-103125.md) | [3.5](/filings/0001193125-25-264821.md) | [4.2 d](/filings/0001193125-26-091656.md) | [3.8](/filings/0001193125-26-206643.md) | [4.3](/filings/0001193125-26-332779.md) | [4.8](/filings/0001193125-25-264821.md) | [3.6 d](/filings/0001193125-26-091656.md) | [2.6](/filings/0001193125-26-206643.md) | [5.5](/filings/0001193125-26-332779.md) |
| Net income | $m | [5.6](/filings/0000950170-24-121492.md) | [9.7](/filings/0000950170-24-027956.md) | [10.4](/filings/0000950170-25-064535.md) | [10.8](/filings/0000950170-25-103125.md) | [12.8](/filings/0001193125-25-264821.md) | [13.7 d](/filings/0001193125-26-091656.md) | [13.6](/filings/0001193125-26-206643.md) | [16.7](/filings/0001193125-26-332779.md) | [18.1](/filings/0001193125-25-264821.md) | [17.9 d](/filings/0001193125-26-091656.md) | [16.4](/filings/0001193125-26-206643.md) | [22.0](/filings/0001193125-26-332779.md) |
| Diluted EPS | $ per share | [0.32](/filings/0000950170-24-121492.md) | not reported | [0.61](/filings/0000950170-25-064535.md) | [0.63](/filings/0000950170-25-103125.md) | [0.74](/filings/0001193125-25-264821.md) | not reported | [0.78](/filings/0001193125-26-206643.md) | [0.96](/filings/0001193125-26-332779.md) | [1.03](/filings/0001193125-25-264821.md) | not reported | [0.88](/filings/0001193125-26-206643.md) | [1.08](/filings/0001193125-26-332779.md) |
| Basic EPS | $ per share | [0.32](/filings/0000950170-24-121492.md) | not reported | [0.68](/filings/0000950170-25-064535.md) | [0.70](/filings/0000950170-25-103125.md) | [0.85](/filings/0001193125-25-264821.md) | not reported | [0.90](/filings/0001193125-26-206643.md) | [1.12](/filings/0001193125-26-332779.md) | [1.22](/filings/0001193125-25-264821.md) | not reported | [1.03](/filings/0001193125-26-206643.md) | [1.25](/filings/0001193125-26-332779.md) |

- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [142](/filings/0000950170-23-060388.md) | [297](/filings/0000950170-25-033724.md) | [368](/filings/0000950170-24-054517.md) | [242](/filings/0000950170-24-094013.md) | [258](/filings/0000950170-24-121492.md) | [371](/filings/0001193125-26-091656.md) | [219](/filings/0000950170-25-064535.md) | [113](/filings/0000950170-25-103125.md) | [116](/filings/0001193125-25-264821.md) | [175](/filings/0001193125-26-332779.md) | [425](/filings/0001193125-26-206643.md) | [404](/filings/0001193125-26-332779.md) |
| Total assets | $m | [4,216](/filings/0000950170-23-060388.md) | [4,396](/filings/0000950170-25-033724.md) | [4,660](/filings/0000950170-24-054517.md) | [4,474](/filings/0000950170-24-094013.md) | [4,628](/filings/0000950170-24-121492.md) | [4,942](/filings/0001193125-26-091656.md) | [4,897](/filings/0000950170-25-064535.md) | [4,944](/filings/0000950170-25-103125.md) | [5,062](/filings/0001193125-25-264821.md) | [5,341](/filings/0001193125-26-332779.md) | [6,582](/filings/0001193125-26-206643.md) | [6,736](/filings/0001193125-26-332779.md) |
| Total liabilities | $m | [3,815](/filings/0000950170-23-060388.md) | [3,984](/filings/0000950170-25-033724.md) | [4,237](/filings/0000950170-24-054517.md) | [4,039](/filings/0000950170-24-094013.md) | [4,177](/filings/0000950170-24-121492.md) | [4,482](/filings/0001193125-26-091656.md) | [4,417](/filings/0000950170-25-064535.md) | [4,448](/filings/0000950170-25-103125.md) | [4,548](/filings/0001193125-25-264821.md) | [4,810](/filings/0001193125-26-332779.md) | [5,932](/filings/0001193125-26-206643.md) | [6,065](/filings/0001193125-26-332779.md) |
| Shareholders' equity | $m | [400](/filings/0000950170-24-121492.md) | [412](/filings/0001193125-26-091656.md) | [424](/filings/0000950170-25-103125.md) | [435](/filings/0001193125-25-264821.md) | [451](/filings/0001193125-25-264821.md) | [461](/filings/0001193125-26-332779.md) | [480](/filings/0001193125-26-332779.md) | [496](/filings/0001193125-26-332779.md) | [514](/filings/0001193125-25-264821.md) | [531](/filings/0001193125-26-332779.md) | [651](/filings/0001193125-26-332779.md) | [671](/filings/0001193125-26-332779.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Total assets: us-gaap:Assets
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [3.1 d](/filings/0000950170-24-121492.md) | [17.5 d](/filings/0001193125-26-091656.md) | [9.4](/filings/0000950170-25-064535.md) | [7.3 d](/filings/0000950170-25-103125.md) | [22.0 d](/filings/0001193125-25-264821.md) | [(3.6) d](/filings/0001193125-26-091656.md) | [10.5](/filings/0001193125-26-206643.md) | [13.9 d](/filings/0001193125-26-332779.md) | [20.7 d](/filings/0001193125-25-264821.md) | [5.7 d](/filings/0001193125-26-091656.md) | [(38.7)](/filings/0001193125-26-206643.md) | [45.0 d](/filings/0001193125-26-332779.md) |
| Capital expenditure | $m | [1.2 d](/filings/0000950170-23-060388.md) | [0.4 d](/filings/0000950170-25-033724.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [13.7](/filings/0000950170-23-060388.md) | [16.8](/filings/0000950170-24-054517.md) | [16.9](/filings/0000950170-24-094013.md) | [13.9](/filings/0000950170-24-121492.md) | [16.9](/filings/0000950170-25-064535.md) | [17.0](/filings/0000950170-25-103125.md) | [17.2](/filings/0001193125-25-264821.md) | [17.4](/filings/0001193125-26-206643.md) | [17.4](/filings/0001193125-26-332779.md) | [17.5](/filings/0001193125-25-264821.md) | [18.6](/filings/0001193125-26-206643.md) | [20.3](/filings/0001193125-26-332779.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 16,654,970 at 2026-07-31, from the cover of the [10-Q filed 2026-08-04](/filings/0001193125-26-332779.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.